GA-TSYS
12.9.2019 14:02:03 CEST | Business Wire | Press release
TSYS (NYSE: TSS) today announced a new authentication product that provides unprecedented real-time verification of customer identities. The new offering, the TSYS Authentication PlatformSM , relies on customer experience data collected from direct cardholder touchpoints and integrates into TSYS clients’ existing authentication systems. TSYS Authentication Platform is available in Europe and will be launched in North America in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005131/en/
The new product is designed to verify that a person is who he or she claims to be, reducing application, transaction and account takeover fraud, while still providing a frictionless customer experience. It’s effective at combatting synthetic identity fraud because it does not rely on reported data, which inherently creates inefficient lag time in the verification process.
The platform utilizes the latest technology – including machine learning – to provide real-time, informed opinions about any type of remote customer interaction or transaction with a financial institution for both consumer and commercial relationships. Examples include originating an account, updating a customer profile, changing a password or making a purchase.
TSYS can provide unparalleled cross-issuer and cross-border insight thanks to its relationships with more than 130 card issuers worldwide.
“At TSYS, we understand how various transactions are connected because we work with a global network of card issuers representing millions of individual accounts,” said Justin Griggs, senior vice president of product strategy and commercialization, TSYS Issuer Solutions. “If a device has been compromised in Ireland, for example, we can use that information to flag a remote login attempt in North America. We have real-time knowledge of potential fraud issues, and now we’re using that information to help our clients authenticate their customers and transactions across any use case.”
The TSYS Authentication Platform aids TSYS customers with their compliance needs to align with the European Union’s Payment Service Directive 2 (PSD2) and Strong Customer Authentication (SCA) provision by providing the ability to flexibly keep pace with the rapidly evolving world of authentication.
TSYS partnered with four key companies to develop the product:
- Featurespace , the leading provider of the award-wining, scalable ARIC™ platform and inventor of Adaptive Behavioral Analytics, previously collaborated with TSYS on the TSYS Foresight Score SM transaction fraud product. The new Authentication Platform utilizes Featurespace’s flexible multi-tenant capabilities that enables an industry-wide view of new fraud vectors for advanced decisioning.
- Emailage is a global leader in online fraud prevention and email risk assessment. Emailage’s technology leverages email address metadata, state of the art machine learning and dynamic data from a global network to generate multi-dimensional identity profiles and render a fraud risk score. This helps users build better informed fraud decision making processes.
- InAuth is a leading digital device intelligence company that specializes in using browser and app information to authenticate online transactions. It will ensure that TSYS clients know and understand the trustworthiness of every device interacting with their digital channels, including mobile app, mobile web and desktop.
- Payfone is the leading digital identity authentication network for the connected world. Their solutions enable consumers and businesses to transact with trust across all channels. Payfone can improve “pass rates” while thwarting synthetic IDs and identity theft with real-time, passive authentication and predictive identity confidence through their proprietary Trust Score™. They will measure the potential risk associated with a digital identity, so users can trust they know who their customers are.
TSYS will continue to enhance its authentication measures to help combat the fraud landscape and expects to leverage additional functionality such as facial recognition, document scanning, and behavioral biometrics, as well as utilize differentiated data sets through 2020 and beyond.
For more information about the TSYS Authentication Platform visit https://www.tsys.com/authentication-platform
About TSYS
TSYS® (NYSE: TSS) is a leading global payments provider, offering seamless, secure and innovative solutions across the payments spectrum — for issuers, merchants and consumers. We succeed because we put people and their needs at the heart of every decision to help them unlock payment opportunities. It’s an approach we call People-Centered Payments® .
Our headquarters are located in Columbus, Ga., U.S.A., with approximately 13,000 team members and local offices across 13 countries. TSYS generated revenue of $4.0 billion in 2018, while processing more than 32.3 billion transactions. We are a member of The Civic 50 and were named one of the 2018 World's Most Ethical Companies by Ethisphere magazine. TSYS is a member of the S&P 500 and routinely posts all important information on its website. For more, visit tsys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
